16 Apr 2009 07:00
16 April 2009 Imperial Innovations Group ("Imperial Innovations") Notice of Half Year Results
Imperial Innovations (AIM: IVO), a leading technology commercialisation and investment company, will announce its half year results, for the six months ended 31 January 2009, on 27 April 2009.
For further information please contact:
Imperial InnovationsSusan Searle, Chief ExecutiveDiana Crisp, PR ManagerTel. +44 (0)20 7594 6589
M:Communications
Patrick d'Ancona or Ben SimonsTel. +44 (0)20 7153 1540JPMorgan Cazenove (NOMAD to Imperial Innovations)Steve BaldwinTel. +44(0)20 7588 2828About Imperial Innovations
Imperial Innovations is one of the UK's leading technology commercialisation and investment companies. Founded in 1986 and admitted to the AIM Market of the London Stock Exchange in 2006, Imperial Innovations' access to early stage technology and intellectual property is unparalleled. Imperial Innovations' integrated commercialisation approach encompasses the identification of ideas, the protection of intellectual property, the development and licensing of technology and the formation, incubation and funding, through investment, of technology businesses.
Based at Imperial College, London, Imperial Innovations' portfolio of equity holdings in more than 80 companies spans across its four core areas of Healthcare, Engineering, Energy & Environment and Software & IT.
Companies in the portfolio include: Nexeon (lithium ion battery technology), Circassia (allergy therapeutics), Polytherics (drug development), Evo Electric (electric motor and generator solutions), Respivert (respiratory drug development), Quantasol (solar concentrators) and Inforsense (business analytics)
Imperial Innovations has already realised significant value from its investments to date including from a recent trade sale in December 2008 when Thiakis Limited, a company in which Imperial Innovations had a 23.7% stake, was sold for up to £100 million to US-based Wyeth Pharmaceuticals.
www.imperialinnovations.co.uk
vendor